— peptide / sexual-health —
Cyclic heptapeptide melanocortin receptor agonist investigated in sexual response research and approved for hypoactive sexual desire disorder.
Palatin Technologies. FDA-approved 2019 (Vyleesi) for specific indication. Kingsberg et al. 2019. Read more →
From Retail $41 USDT
Member $36.00 USDT
Members save 15% — free to join
Order now to reserve — we'll ship as soon as inventory is replenished.
Research-grade material. Documentation summarizes published literature in third-person scientific context. Not medical advice; not for human consumption.
— Pricing —
All prices in USDT. Crypto pays settle directly to our wallet.
Single vial
Retail $41 USDT
Member $36.00 USDT
Members save 15% — free to join
1 vial · $36.00 USDT per vial
Most flexible
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
5-Pack
Save 15%Retail $176 USDT
Member $153.00 USDT
Members save 15% — free to join
5 vials · $30.60 USDT per vial
Researcher's choice
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
10-Pack
Best valueRetail $256 USDT
Member $223.00 USDT
Members save 15% — free to join
10 vials · $22.30 USDT per vial
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
— The literature —
Bremelanotide engages multiple melanocortin receptor subtypes with a preference for MC4R, the principal receptor mediating central regulation of energy balance, sexual response, and certain behavioral effects. MC4R is a class A G-protein coupled receptor expressed prominently in hypothalamus, brainstem, and limbic structures, and is coupled to Gas with downstream cAMP elevation.
The proposed mechanism of action in sexual response involves engagement of MC4R in central nuclei including the paraventricular nucleus and medial preoptic area, with downstream effects on oxytocinergic, dopaminergic, and other neurotransmitter systems implicated in sexual desire. The compound does not act on peripheral vascular targets that mediate the effects of PDE5 inhibitors, supporting a centrally-mediated rather than peripherally-mediated mechanism. Bremelanotide also retains affinity at MC1R, the receptor responsible for pigmentation effects of alpha-MSH, and at MC3R, with potential contributions to observed effects on appetite and energy balance in some preclinical studies.
All compounds discussed are intended for research use only. Not for human consumption. Research-context information is educational and does not constitute medical advice.
View the full disclaimer →